The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | L | Antineoplastic and immunomodulating agents | |
| 2 | L01 | Antineoplastic agents | |
| 3 | L01E | Protein kinase inhibitors | |
| 4 | L01EL | Bruton's tyrosine kinase (BTK) inhibitors | |
| 5 | L01EL03 |
| Active Ingredient | Description | |
|---|---|---|
| Zanubrutinib |
Zanubrutinib is a small-molecule inhibitor of BTK. BTK is a signaling molecule of the B-cell antigen receptor (BCR) and cytokine receptor pathways. In B-cells, BTK signaling results in activation of pathways necessary for B-cell proliferation, trafficking, chemotaxis, and adhesion. Zanubrutinib is used for the treatment of adult patients with mantle cell lymphoma (MCL). |
| Title | Information Source | Document Type | |
|---|---|---|---|
| BRUKINSA Capsule | FDA, National Drug Code (US) | MPI, US: SPL/PLR |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
